Tandem Stock Based Compensation To Revenue from 2010 to 2024
| TNDM Stock | USD 30.63 0.59 1.89% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.11779307 | Current Value 0.15 | Quarterly Volatility 0.05270505 |
Check Tandem Diabetes financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tandem Diabetes' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8 M, Interest Expense of 6 M or Selling General Administrative of 370.1 M, as well as many indicators such as Price To Sales Ratio of 2.44, Dividend Yield of 0.0 or PTB Ratio of 4.71. Tandem financial statements analysis is a perfect complement when working with Tandem Diabetes Valuation or Volatility modules.
Tandem | Stock Based Compensation To Revenue |
Latest Tandem Diabetes' Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Tandem Diabetes Care over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Tandem Diabetes' Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tandem Diabetes' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Tandem Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 0.14 | |
| Geometric Mean | 0.13 | |
| Coefficient Of Variation | 38.46 | |
| Mean Deviation | 0.03 | |
| Median | 0.12 | |
| Standard Deviation | 0.05 | |
| Sample Variance | 0 | |
| Range | 0.2151 | |
| R-Value | (0.11) | |
| Mean Square Error | 0 | |
| R-Squared | 0.01 | |
| Significance | 0.69 | |
| Slope | (0) | |
| Total Sum of Squares | 0.04 |
Tandem Stock Based Compensation To Revenue History
About Tandem Diabetes Financial Statements
Tandem Diabetes investors utilize fundamental indicators, such as Stock Based Compensation To Revenue, to predict how Tandem Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.12 | 0.15 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Tandem Diabetes Correlation against competitors. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share 13.082 | Quarterly Revenue Growth 0.314 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.